These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19170302)

  • 61. Double-blind randomized multicenter dose-comparison study of interferon-beta-1a (AVONEX): rationale, design and baseline data.
    Mult Scler; 2001 Jun; 7(3):179-83. PubMed ID: 11475442
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study.
    Wray S; Hayward B; Dangond F; Singer B
    Expert Opin Drug Deliv; 2018 Feb; 15(2):127-135. PubMed ID: 29206056
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
    Baum K; O'Leary C; Coret Ferrer F; Klímová E; Procházková L; Bugge J;
    Mult Scler; 2007 Nov; 13(9):1153-60. PubMed ID: 17967843
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparison of 3 needle sizes for trigger point injection in myofascial pain syndrome of upper- and middle-trapezius muscle: a randomized controlled trial.
    Yoon SH; Rah UW; Sheen SS; Cho KH
    Arch Phys Med Rehabil; 2009 Aug; 90(8):1332-9. PubMed ID: 19651267
    [TBL] [Abstract][Full Text] [Related]  

  • 65. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.
    Vollmer TL; Phillips JT; Goodman AD; Agius MA; Libonati MA; Giacchino JL; Grundy JS
    Mult Scler; 2004 Oct; 10(5):511-20. PubMed ID: 15471366
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
    Simon JH; Jacobs LD; Campion M; Wende K; Simonian N; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Alam JJ; Fischer JS; Goodkin DE; Granger CV; Lajaunie M; Martens-Davidson AL; Meyer M; Sheeder J; Choi K; Scherzinger AL; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Whitham RH
    Ann Neurol; 1998 Jan; 43(1):79-87. PubMed ID: 9450771
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
    Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
    Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a.
    Kita M; Goodkin DE; Bacchetti P; Waubant E; Nelson SJ; Majumdar S
    Neurology; 2000 May; 54(9):1741-5. PubMed ID: 10802778
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis.
    Mikol D; Lopez-Bresnahan M; Taraskiewicz S; Chang P; Rangnow J;
    Mult Scler; 2005 Oct; 11(5):585-91. PubMed ID: 16193898
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Interferon beta assessment in non-Chinese and Chinese subjects: pharmacokinetics and pharmacodynamic activity of an endogenous cytokine are not race dependent.
    Rogge MC; Liu Y; Galluppi GR
    J Clin Pharmacol; 2014 Oct; 54(10):1153-61. PubMed ID: 24737408
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Needle size for vaccination procedures in children and adolescents.
    Beirne PV; Hennessy S; Cadogan SL; Shiely F; Fitzgerald T; MacLeod F
    Cochrane Database Syst Rev; 2015 Jun; (6):CD010720. PubMed ID: 26086647
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy.
    Trojano M; Liguori M; Paolicelli D; Zimatore GB; De Robertis F; Avolio C; Giuliani F; Fuiani A; Livrea P;
    Mult Scler; 2003 Oct; 9(5):451-7. PubMed ID: 14582768
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
    Murray TJ
    Curr Med Res Opin; 2004 Jan; 20(1):25-30. PubMed ID: 14741068
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate.
    Jolly H; Simpson K; Bishop B; Hunter H; Newell C; Denney D; Oleen-Burkey M
    J Neurosci Nurs; 2008 Aug; 40(4):232-9. PubMed ID: 18727339
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Nursing service for MS patients].
    Krankenpfl J; 2005; 43(7-10):235. PubMed ID: 16518890
    [No Abstract]   [Full Text] [Related]  

  • 76. Injection anxiety and pain in men using intracavernosal injection therapy after radical pelvic surgery.
    Nelson CJ; Hsiao W; Balk E; Narus J; Tal R; Bennett NE; Mulhall JP
    J Sex Med; 2013 Oct; 10(10):2559-65. PubMed ID: 23898886
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The importance of maintaining effective therapy in multiple sclerosis.
    Durelli L; Clerico M
    J Neurol; 2005 Sep; 252 Suppl 3():iii38-iii43. PubMed ID: 16170500
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.
    Chofflon M; Ben-Amor AF
    Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662
    [No Abstract]   [Full Text] [Related]  

  • 79. Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.
    Miller DM; Weinstock-Guttman B; Bourdette D; You X; Foulds P; Rudick RA
    Mult Scler; 2011 Jun; 17(6):734-42. PubMed ID: 21300736
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Needle preference in patients receiving cosmetic botulinum toxin type A.
    Price KM; Williams ZY; Woodward JA
    Dermatol Surg; 2010; 36(1):109-12. PubMed ID: 20002642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.